Relay Therapeutics, Inc. Stock Analysis & AI Score
Relay Therapeutics, Inc. (RLAY) has an ST Score of 56.9 (B-), driven by its Sentiment (A+) and held back by its Growth (D-). Analysts rate it Buy with a $26.25 price target (+48.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Relay Therapeutics, Inc. (RLAY) has an ST Score of 56.9 (B-), driven by its Sentiment (A+) and held back by its Growth (D-). Analysts rate it Buy with a $26.25 price target (+48.1% upside).
- Strongest
- SentimentA+
- Weakest
- GrowthD-
All factor grades
- SentimentA+
- Financial StrengthB+
- ProfitabilityB
- MomentumB
- ForecastB
- ValuationB-
- GrowthD-
- Piotroski3/9
Contact
RLAY stock: frequently asked questions
What is RLAY's ST Score?
Relay Therapeutics, Inc. (RLAY) has an ST Score of 56.9 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is RLAY a buy, hold, or sell?
Analysts rate RLAY a Buy, with a price target of $26.25 (+48.1% vs the current price). Our ST Score grades it B- (56.9/100). The ST Score is a data-driven signal, not a recommendation.
What are RLAY's factor grades?
Valuation B-, Profitability B, Financial Strength B+, Momentum B, Growth D-, Forecast B, Sentiment A+.
What is RLAY's valuation grade?
Relay Therapeutics, Inc. (RLAY) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is RLAY's growth grade?
Relay Therapeutics, Inc. (RLAY) earns a growth grade of D-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is RLAY's profitability grade?
Relay Therapeutics, Inc. (RLAY) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is RLAY's financial strength grade?
Relay Therapeutics, Inc. (RLAY) earns a financial strength grade of B+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for RLAY?
The average analyst price target for Relay Therapeutics, Inc. (RLAY) is $26.25 from 15 analysts, which is +48.1% versus the recent price of $17.73.
What is RLAY's Piotroski score?
Relay Therapeutics, Inc. (RLAY) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.